HCC patients also presented elevated levels of liver enzymes compared to patients with benign tumors (ALT 39.9 vs 24.4, p = 0.2 and AST 44.9 vs 23.4, p = 0.01), a trend also observed in CCA patients (ALT 45.2 vs 24.4, p = 0.06 and AST 46.5 vs 26.5, p < 0.05). This evidence concerns the gene GPT and cholangiocarcinoma.